Holen Sie sich die Stockscreener-App
89.51
0.78%
0.69
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lowered by Private Management Group Inc. - MarketBeat
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Gilead Oncology Grant Supports 22 U.S. Organizations With - CSRwire.com
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by AustralianSuper Pty Ltd - MarketBeat
Gilead Oncology Grant Supports 22 U.S. Organizations With $3.15 Million to Provide Support to Those Affected By Breast Cancer - Marketscreener.com
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies - AccessWire
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by New York State Teachers Retirement System - MarketBeat
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline - Yahoo Finance
Gilead Sciences (GILD) to Release Quarterly Earnings on Wednesday - MarketBeat
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Gilead Sciences (NASDAQ:GILD) Given Sector Perform Rating at Royal Bank of Canada - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Private Advisor Group LLC Sells 5,794 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
GILD (Gilead Sciences) Owner Earnings per Share (TTM) : -1.70 (As of Jun. 2024) - GuruFocus.com
Hennion & Walsh Asset Management Inc. Sells 7,644 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
International Assets Investment Management LLC Buys 1,622,806 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Cullinan Associates Inc. Sells 14,347 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - STAT
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - Yahoo Finance
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences (NASDAQ:GILD) Sets New 12-Month HighStill a Buy? - MarketBeat
Spain CAR-T Cell Therapy Market Forecast to 2029, Featuring - GlobeNewswire
Lazari Capital Management Inc. Cuts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead stock touches 52-week high at $87.9 amid robust growth - Investing.com
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024 - BioSpace
Gilead and MSD to advance once-weekly HIV treatment to Phase III - Yahoo Finance
Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know - Nasdaq
Gilead Sciences’ Quarterly Earnings Preview: What You Need To Know - Barchart
Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Creative Planning Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks - AOL
Gilead, MRK Report Data From Investigational Combination Study for HIV - Zacks Investment Research
Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Bellecapital International Ltd. - MarketBeat
Gilead upgraded to outperform by Leerink on PrEP outlook (NASDAQ:GILD) - Seeking Alpha
Gilead and Merck tout first weekly oral HIV treatment - The Pharma Letter
Gilead retains Outperform rating from BMO Capital - Investing.com India
Peering Into Gilead Sciences's Recent Short Interest - Benzinga
Evaluating Gilead Sciences: Insights From 15 Financial Analysts - Benzinga
Gilead Sciences (NASDAQ:GILD) Upgraded by Leerink Partners to Outperform - MarketBeat
Gilead to withdraw Trodelvy indication in USA - The Pharma Letter
Gilead, MSD say HIV combo could be weekly, oral HIV drug - pharmaphorum
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 - BioSpace
Stratos Investment Management LLC Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
0.74%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):